Publications by authors named "Joanna Wojcik-Tomaszewska"
Article Synopsis
- Nivolumab, an immunotherapy drug, significantly improves overall survival rates in patients with advanced non-small-cell lung cancer (NSCLC) compared to the traditional chemotherapy drug docetaxel, as shown in the CheckMate 017 and CheckMate 057 trials.
- In a pooled analysis of 854 patients, 5-year overall survival rates for nivolumab treatment were 13.4%, compared to just 2.6% for docetaxel, and progression-free survival rates were 8.0% for nivolumab versus 0% for docetaxel.
- The findings indicate that nivolumab remains effective with manageable side effects even after 5 years, with no new safety concerns
Background: Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab versus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We aimed to evaluate the long-term benefit of nivolumab and the effect of response and disease control on subsequent survival.
Methods: We pooled data from four clinical studies of nivolumab in patients with previously treated NSCLC (CheckMate 017, 057, 063, and 003) to evaluate survival outcomes.